Trials / Completed
CompletedNCT03820908
Bisantrene for Relapsed /Refractory AML
Bisantrene for Relapsed /Refractory Acute Myelogenous Leukemia (AML)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Sheba Medical Center · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Induction of response in patients with AML that are either primary resistant (failed induction and or salvage therapy) or relapsed including post allogeneic stem cell transplantation and failed salvage therapy or cannot receive additional anthracycline .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bisantrene | The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care. |
Timeline
- Start date
- 2019-07-18
- Primary completion
- 2020-05-19
- Completion
- 2020-07-22
- First posted
- 2019-01-29
- Last updated
- 2020-08-07
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT03820908. Inclusion in this directory is not an endorsement.